NASDAQ: LGVNLongeveron Inc Stock
$0.76-0.10 (-11.63%)
Updated Aug 14, 2025
LGVN Price
$0.76
Fair Value Price
N/A
Market Cap
$11.46M
52 Week Low
$0.63
52 Week High
$2.86
P/E
-0.82x
P/B
0.91x
P/S
9.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.07M
Earnings
-$18.54M
Gross Margin
78.8%
Operating Margin
-894.31%
Profit Margin
-901.5%
Debt to Equity
0.32
Operating Cash Flow
-$15M
Beta
1.2
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LGVN Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LGVN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LGVN
Ranked#445 of 481
Ranked#445 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.94 | A | |
| $12.09 | A | |
| $37.89 | A |
Be the first to know about important LGVN news, forecast changes, insider trades & much more!
LGVN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LGVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LGVN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LGVN is good value based on its book value relative to its share price (0.91x), compared to the US Biotechnology industry average (4.42x)
P/B vs Industry Valuation
LGVN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LGVN due diligence checks available for Premium users.
Valuation
LGVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.82x
Industry
-116.18x
Market
36.29x
LGVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
4.42x
LGVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LGVN's financial health
Profit margin
Revenue
$316.0k
Net Income
-$5.0M
Profit Margin
-1,591.1%
LGVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LGVN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.7M
Liabilities
$4.1M
Debt to equity
0.32
LGVN's short-term assets ($11.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LGVN's short-term assets ($11.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LGVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
-$263.0k
Financing
-$133.0k
LGVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LGVN vs Biotech Stocks
Longeveron Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.